Zacks Investment Research upgraded shares of PROGENICS PHARM (PGNX) from UNDERPERFORM to NEUTRAL on October 01, 2012, with a target price of $3.00.
Progenics Pharmaceuticals, Inc. is a biopharmaceutical company focusing on the development & commercialization of innovative therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. Principal programs are directed toward symptom management and supportive care and the treatment of HIV infection and cancer. The Company has four product candidates in clinical development and several others in preclinical development. The Company in collaboration with Wyeth, is developing methylnaltrexone for the treatment of opioid-induced side effects, including constipation and post-operative ileus. In the area of HIV infection, the Company is developing the viral-entry inhibitor PRO one hundred forty, a humanized monoclonal antibody targeting the HIV coreceptor CCR5. In addition, the Company is conducting research on ProVax, a novel prophylactic HIV vaccine.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on PROGENICS PHARM (PGNX),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment